Indobufen-crystal patent faces new challenge in China despite past failures
A pharmaceutical patent held by Hangzhou Zhongmei Huadong Pharmaceutical — upheld multiple times over the past year by China’s intellectual property authority despite repeated invalidation attempts — is now facing a...To view the full article, register now.
Already a subscriber? Click here to view full article